LASS2 和 TGF-β1 的共表达可预测肝细胞癌的不良预后。

Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma.

机构信息

State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.

出版信息

Sci Rep. 2016 Sep 1;6:32421. doi: 10.1038/srep32421.

DOI:10.1038/srep32421

PMID:27581744

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5007525/

Abstract

Longevity assurance homolog 2 of yeast LAG1 (LASS2) has been reported to act as an important tumor suppressor in the development of human cancers. However, little is known about the prognostic value of LASS2 in hepatocellular carcinoma (HCC) . In the present study, we analyzed correlation between LASS2 and TGF-β1 levels, and evaluated their prognostic values in HCC patients. We first analyzed the expression of LASS2 and TGF-β1 in two independent cohorts (test cohort: 184 HCC patients; validation cohort: 118 HCC patients) using immunohistochemistry (IHC). Kaplan-Meier survival and Cox regression analyses were executed to evaluate the prognosis of HCC. The results of IHC analysis revealed a positive correlation between the expression of LASS2 and TGF-β1. HCC Patients with low expression of LASS2 and TGF-β1 had shorter overall survival (OS) and time to recurrence (TTR) than patients with high expression of LASS2 and TGF-β1. Furthermore, combination of LASS2 and TGF-β1 was an independent and significant risk factor for OS and TTR. In conclusion, low expression of LASS2 and TGF-β1 contributes to the aggressiveness and poor prognosis of HCC, and may represent a novel prognostic biomarker for HCC patients.

摘要

酵母 LAG1 的长寿保证同源物 2（LASS2）已被报道作为人类癌症发展中的重要肿瘤抑制因子。然而，对于 LASS2 在肝细胞癌（HCC）中的预后价值知之甚少。在本研究中，我们分析了 LASS2 和 TGF-β1 水平之间的相关性，并评估了它们在 HCC 患者中的预后价值。我们首先使用免疫组织化学（IHC）分析了两个独立队列（测试队列：184 名 HCC 患者；验证队列：118 名 HCC 患者）中 LASS2 和 TGF-β1 的表达。进行 Kaplan-Meier 生存和 Cox 回归分析以评估 HCC 的预后。IHC 分析的结果显示 LASS2 和 TGF-β1 的表达呈正相关。LASS2 和 TGF-β1 低表达的 HCC 患者的总生存期（OS）和复发时间（TTR）短于 LASS2 和 TGF-β1 高表达的患者。此外，LASS2 和 TGF-β1 的组合是 OS 和 TTR 的独立显著危险因素。总之，LASS2 和 TGF-β1 的低表达导致 HCC 的侵袭性和预后不良，可能代表 HCC 患者的一种新的预后生物标志物。